Literature DB >> 1180750

Clinical experience with a mobile ocular perfusion pump.

R A Ralph, M G Doane, C H Dohlman.   

Abstract

The continuous delivery in fluids to the ocular surfaces of 12 patients, for a collective total of 1,500 days, was achieved by means of a mobile perfusion pump. One patient used this device intermittently for a total of 21/2 years. Severe dry-eye symptoms were ameliorated in each patient by the constant perfusion. In various situations, the following perfusion fluids have been tried: commercial balanced salt solution, commercial artificial tear solutions, acetylcysteine, and autologous and homologous serum and plasma. In spite of disadvantages related to its size and weight, the pump seems to be of considerable value, especially following severe chemical burns and after keratoplasty or reconstruction of the lids and fornices in the severely dry eye.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1180750     DOI: 10.1001/archopht.1975.01010020815015

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  19 in total

1.  Serum eye drops for the treatment of ocular surface diseases: a systematic review and meta-analysis.

Authors:  Massimo Franchini; Mario Cruciani; Carlo Mengoli; Giuseppe Marano; Enrico Capuzzo; Ilaria Pati; Francesca Masiello; Eva Veropalumbo; Simonetta Pupella; Stefania Vaglio; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2019-05       Impact factor: 3.443

2.  Use of eye drops obtained from homologous blood source in the time of COVID-19: is there cause for ophthalmological concern?

Authors:  Giuseppe Giannaccare; Marina Buzzi; Piera Versura
Journal:  Blood Transfus       Date:  2020-05       Impact factor: 3.443

3.  Human albumin eye drops as a therapeutic option for the management of keratoconjunctivitis sicca secondary to chronic graft-versus-host disease after stem-cell allografting.

Authors:  J T Seki; N Sakurai; S Moldenhauer; J Dam; E G Atenafu; P M Yip; T Mazzulli; T Henderson; J Pendergrast; C Cserti; J P Velazquez; R Simpson; G Felluga; H A Messner; J H Lipton
Journal:  Curr Oncol       Date:  2015-10       Impact factor: 3.677

Review 4.  Autologous serum eye drops for dry eye.

Authors:  Qing Pan; Adla Angelina; Andrea Zambrano; Michael Marrone; Walter J Stark; Thomas Heflin; Li Tang; Esen K Akpek
Journal:  Cochrane Database Syst Rev       Date:  2013-08-27

Review 5.  Neuropathic Corneal Pain: Approaches for Management.

Authors:  Gabriela Dieckmann; Sunali Goyal; Pedram Hamrah
Journal:  Ophthalmology       Date:  2017-11       Impact factor: 12.079

Review 6.  Autologous serum eye drops for dry eye.

Authors:  Qing Pan; Adla Angelina; Michael Marrone; Walter J Stark; Esen K Akpek
Journal:  Cochrane Database Syst Rev       Date:  2017-02-28

7.  Evaluation of the efficacy of 50% autologous serum eye drops in different ocular surface pathologies.

Authors:  Francesco Semeraro; Eliana Forbice; Osvaldo Braga; Alessandro Bova; Attilio Di Salvatore; Claudio Azzolini
Journal:  Biomed Res Int       Date:  2014-07-22       Impact factor: 3.411

Review 8.  Human Serum Eye Drops in Eye Alterations: An Insight and a Critical Analysis.

Authors:  Maria Rosaria De Pascale; Michele Lanza; Linda Sommese; Claudio Napoli
Journal:  J Ophthalmol       Date:  2015-10-04       Impact factor: 1.909

9.  Topical 100% serum eye drops for treating corneal epithelial defect after ocular surgery.

Authors:  Kaevalin Lekhanont; Passara Jongkhajornpong; Lulin Choubtum; Varintorn Chuckpaiwong
Journal:  Biomed Res Int       Date:  2013-07-30       Impact factor: 3.411

10.  The use of autologous serum for the treatment of ocular surface disease at a Swedish tertiary referral center.

Authors:  Joanna von Hofsten; Maria Egardt; Madeleine Zetterberg
Journal:  Int Med Case Rep J       Date:  2016-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.